Invivyd (NASDAQ:IVVD) Given “Buy” Rating at D. Boral Capital

Invivyd (NASDAQ:IVVD)‘s stock had its “buy” rating restated by stock analysts at D. Boral Capital in a research note issued to investors on Monday,Benzinga reports. They presently have a $9.00 price target on the stock. D. Boral Capital’s price target indicates a potential upside of 408.47% from the stock’s previous close.

Other research analysts have also recently issued research reports about the stock. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Invivyd in a report on Tuesday, February 4th. Morgan Stanley lowered their target price on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research note on Wednesday, November 20th. Finally, EF Hutton Acquisition Co. I raised Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Invivyd currently has a consensus rating of “Buy” and an average target price of $7.89.

Invivyd Stock Performance

Shares of IVVD opened at $1.77 on Monday. The stock has a 50-day simple moving average of $0.79 and a 200-day simple moving average of $0.86. Invivyd has a 1 year low of $0.35 and a 1 year high of $4.74. The stock has a market capitalization of $211.73 million, a PE ratio of -0.90 and a beta of 0.61.

Insiders Place Their Bets

In other news, Director Terrance Mcguire sold 160,400 shares of the company’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $0.59, for a total value of $94,636.00. Following the completion of the transaction, the director now owns 4,202,679 shares in the company, valued at approximately $2,479,580.61. This represents a 3.68 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Over the last quarter, insiders have sold 816,466 shares of company stock valued at $423,214. 17.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Invivyd

A number of institutional investors and hedge funds have recently bought and sold shares of IVVD. Proficio Capital Partners LLC purchased a new position in shares of Invivyd during the third quarter worth about $27,000. Jane Street Group LLC grew its stake in Invivyd by 290.5% during the 4th quarter. Jane Street Group LLC now owns 117,432 shares of the company’s stock worth $52,000 after buying an additional 87,358 shares during the last quarter. Barclays PLC grew its stake in Invivyd by 7.8% during the 4th quarter. Barclays PLC now owns 127,180 shares of the company’s stock worth $56,000 after buying an additional 9,207 shares during the last quarter. Renaissance Technologies LLC acquired a new position in Invivyd during the fourth quarter worth approximately $74,000. Finally, JPMorgan Chase & Co. lifted its stake in Invivyd by 644.1% in the fourth quarter. JPMorgan Chase & Co. now owns 256,900 shares of the company’s stock valued at $114,000 after buying an additional 222,375 shares during the last quarter. 70.36% of the stock is owned by hedge funds and other institutional investors.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.